Lupus Foundation of America9d
New Study Identifies Predictors of Successful Glucocorticoid Discontinuation in Systemic Lupus Erythematosus Treatment
A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...
Lupus Foundation of America7d
Investigator-initiated Study of CNTY-101, for People with Autoimmune Diseases, Including Systemic Lupus Erythematosus and Lupus Nephritis Anno…
An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of ...
Lupus Foundation of America1d
2025 Portland Lupus & You Empowerment Conference
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas Join us for the 2025 Portland Lupus & You Empowerment Conference! Lupus ...
Lupus Foundation of America17d
Exagen Inc. Gains Approval for Advanced Lupus and Rheumatoid Arthritis Diagnostic Tests
Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker ...
Lupus Foundation of America16d
UPDATE: Phase 1 Trial Begins for Investigational Therapy, CB-010, for Lupus Nephritis Treatment
The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.